ESMO 2017 | Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS
Trabectedin and pazopanib are agents used to treat patients suffering from leiomyosarcoma (LMS), however there have not been any clinical trials to directly compare their efficacy. Here, Robin Jones, BSc, MB BS, MRCP, MD (Res), from The Royal Marsden NHS Foundation Trust, London, UK, discusses a recent study which compared the data obtained from two separate Phase III randomized clinical trials – SAR 3007 (NCT01343277) which assessed trabectedin, and PALETTE (NCT00753688) which examined the efficacy of pazopanib. Dr Jones explains how the matched indirect comparison study was carried out, and tells us what was concluded from the results. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
Get great new content delivered to your inboxSign up